Comparison of the 5 measurements of the bone markers for the ALN group and the placebo group
. | ALN . | Placebo . | P . |
|---|---|---|---|
| Baseline | |||
| n | 17 | 17 | |
| Bone ALP | 16.41 ± 6.33 | 18.65 ± 16.08 | .2937 |
| OC | 4.61 ± 1.38 | 6.01 ± 2.06 | .0233 |
| NTx | 35.69 ± 24.63 | 56.08 ± 46.50 | .1212 |
| D-PYD | 4.81 ± 2.32 | 6.21 ± 2.71 | .1092 |
| Vitamin D-25 | 20.32 ± 8.94 | 21.83 ± 11.00 | .6584 |
| Follow-up at 6 mo | |||
| n | 15 | 15 | |
| Bone ALP | 10.01 ± 4.73 | 17.33 ± 9.21 | .0123 |
| OC | 3.18 ± 1.17 | 5.74 ± 1.49 | < .0001 |
| NTx | 21.77 ± 14.30 | 46.40 ± 28.26 | .0086 |
| D-PYD | 6.01 ± 6.01 | 5.89 ± 3.09 | .9428 |
| Vitamin D-25 | 28.41 ± 11.38 | 25.36 ± 8.97 | .4213 |
| Follow-up at 12 mo | |||
| n | 13 | 12 | |
| Bone ALP | 8.30 ± 3.16 | 17.95 ± 7.60 | .0010 |
| OC | 2.58 ± 0.64 | 5.46 ± 2.26 | .0010 |
| NTx | 25.92 ± 29.61 | 45.91 ± 24.0 | .0886 |
| D-PYD | 3.95 ± 1.91 | 8.00 ± 3.65 | .0034 |
| Vitamin D-25 | 23.65 ± 9.85 | 29.45 ± 8.71 | .1337 |
| Follow-up at 18 mo | |||
| n | 9 | 11 | |
| Bone ALP | 13.90 ± 6.14 | 23.76 ± 11.23 | .0301 |
| OC | 2.88 ± 0.88 | 5.90 ± 1.36 | < .0001 |
| NTx | 13.57 ± 6.27 | 35.03 ± 18.82 | .0058 |
| D-PYD | 3.79 ± 1.23 | 5.59 ± 2.28 | .0505 |
| Vitamin D-25 | 25.26 ± 9.13 | 26.10 ± 6.33 | .8100 |
| Follow-up at 24 mo | |||
| n | 4 | 3 | |
| Bone ALP | 11.58 ± 6.01 | 16.0 ± 9.01 | .4667 |
| OC | 2.25 ± 1.20 | 5.0 ± 1.74 | .0545 |
| NTx | 11.58 ± 2.66 | 43.90 ± 6.54 | .0003 |
| D-PYD | 2.50 ± 0.73 | 5.60 ± 2.57 | .0651 |
| Vitamin D-25 | 19.58 ± 10.22 | 23.67 ± 15.31 | .6861 |
. | ALN . | Placebo . | P . |
|---|---|---|---|
| Baseline | |||
| n | 17 | 17 | |
| Bone ALP | 16.41 ± 6.33 | 18.65 ± 16.08 | .2937 |
| OC | 4.61 ± 1.38 | 6.01 ± 2.06 | .0233 |
| NTx | 35.69 ± 24.63 | 56.08 ± 46.50 | .1212 |
| D-PYD | 4.81 ± 2.32 | 6.21 ± 2.71 | .1092 |
| Vitamin D-25 | 20.32 ± 8.94 | 21.83 ± 11.00 | .6584 |
| Follow-up at 6 mo | |||
| n | 15 | 15 | |
| Bone ALP | 10.01 ± 4.73 | 17.33 ± 9.21 | .0123 |
| OC | 3.18 ± 1.17 | 5.74 ± 1.49 | < .0001 |
| NTx | 21.77 ± 14.30 | 46.40 ± 28.26 | .0086 |
| D-PYD | 6.01 ± 6.01 | 5.89 ± 3.09 | .9428 |
| Vitamin D-25 | 28.41 ± 11.38 | 25.36 ± 8.97 | .4213 |
| Follow-up at 12 mo | |||
| n | 13 | 12 | |
| Bone ALP | 8.30 ± 3.16 | 17.95 ± 7.60 | .0010 |
| OC | 2.58 ± 0.64 | 5.46 ± 2.26 | .0010 |
| NTx | 25.92 ± 29.61 | 45.91 ± 24.0 | .0886 |
| D-PYD | 3.95 ± 1.91 | 8.00 ± 3.65 | .0034 |
| Vitamin D-25 | 23.65 ± 9.85 | 29.45 ± 8.71 | .1337 |
| Follow-up at 18 mo | |||
| n | 9 | 11 | |
| Bone ALP | 13.90 ± 6.14 | 23.76 ± 11.23 | .0301 |
| OC | 2.88 ± 0.88 | 5.90 ± 1.36 | < .0001 |
| NTx | 13.57 ± 6.27 | 35.03 ± 18.82 | .0058 |
| D-PYD | 3.79 ± 1.23 | 5.59 ± 2.28 | .0505 |
| Vitamin D-25 | 25.26 ± 9.13 | 26.10 ± 6.33 | .8100 |
| Follow-up at 24 mo | |||
| n | 4 | 3 | |
| Bone ALP | 11.58 ± 6.01 | 16.0 ± 9.01 | .4667 |
| OC | 2.25 ± 1.20 | 5.0 ± 1.74 | .0545 |
| NTx | 11.58 ± 2.66 | 43.90 ± 6.54 | .0003 |
| D-PYD | 2.50 ± 0.73 | 5.60 ± 2.57 | .0651 |
| Vitamin D-25 | 19.58 ± 10.22 | 23.67 ± 15.31 | .6861 |
ALN and placebo values for bone ALP, OC, NTx, D-PYD, and vitamin D-25 represent the mean ± standard deviation. Bone ALP indicates serum alkaline phosphatase, bone-specific fraction; OC, serum osteocalcin; NTx, urine type I collagen amino-terminal telopeptide; and D-PYD, urine Pyrilinks-D type I collagen cross-linked peptide.